# Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

> **NCT03960840** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 217 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Diffuse Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia
- Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Rapcabtagene autoleucel single agent
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03960840
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-26
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960840, "Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03960840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*